Hyperammoniemia: new aspects of etiopathogenesis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Current review presents the data of numerous studies on hyperammonemia (HA) performed over the past few years. As practice shows, the use of medicamentous therapy aimed at reducing elevated levels of ammonia in human organism, as well as relieving HA clinical manifestations, such as asthenia, fatigue, and hepatic encephalopathy, is becoming increasingly important. L-ornithine-L-aspartate currently plays a leading role in the treatment of this pathology. At the same time, active searches for new effective methods for treating HA are continuing.

Full Text

Restricted Access

About the authors

Anastasia A. Pan

Far Eastern State Medical University of the Ministry of Healthcare of Russia

Author for correspondence.
Email: gjpbbnbdd@mail.ru
ORCID iD: 0009-0006-1606-5919

cardiologist at Clinical Hospital «RZD-Medicine»

Russian Federation, Khabarovsk

Irina V. Zaykova-Khelimskaya

Far Eastern State Medical University of the Ministry of Healthcare of Russia

Email: irinavh@mail.ru
ORCID iD: 0000-0002-7517-4027

MD, professor, employee of the Department of hospital therapy, Far Eastern State Medical University of the Ministry of Healthcare of Russia

Russian Federation, Khabarovsk

Sergey A. Alexeenko

Far Eastern State Medical University of the Ministry of Healthcare of Russia

Email: sa.alexeenko@gmail.com
ORCID iD: 0000-0003-1724-9980

MD, professor, head of the Department of hospital therapy, Far Eastern State Medical University of the Ministry of Healthcare of Russia

Russian Federation, Khabarovsk

References

  1. Лекции по белкам. Биохимия. ТГМУ. 2005; с. 13. [Lectures on proteins. Biochemistry. Pacific State Medical University. 2005; p. 13 (In Russ.)].
  2. Лазебник Л.Б., Голованова Е.В., Алексеенко С.А. с соавт. Российский консенсус «Гипераммониемии у взрослых» (версия 2021). Экспериментальная и клиническая гастроэнтерология. 2021; (3): 97–118. [Lazebnik L.B., Golovanova E.V., Alekseenko S.A. et al. Russian consensus «Hyperammonemia in adults» (version 2021). Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2021; (3): 97–118 (In Russ.)]. https://dx.doi.org/10.31146/1682-8658-ecg-187-3-97-118. EDN: IXZDGZ.
  3. Алексеенко С.А., Агеева Е.А., Полковникова О.П. Современные подходы к диагностике и лечению гипераммониемии у пациентов с хроническими заболеваниями печени на доцирротической стадии. РМЖ. Медицинское обозрение. 2018; 2(7–1): 19–23. [Alekseenko S.A., Ageeva E.A., Polkovnikova O.P. Modern approaches to the diagnosis and treatment of hyperammonemia in patients with chronic liver diseases at the pre-cirrhotic stage. Russkiy meditsinskiy zhurnal. Meditsinskoye obozreniye = Russian Medical Journal. Medical Review. 2018; 2(7–1): 19–23 (In Russ.)]. EDN: YAUTVB.
  4. Wang Q., Guan K., Lv Y. et al. Disturbance of hepatocyte growth and metabolism in a hyperammonemia microenvironment. Arch Biochem Biophys. 2022; 716: 109109. https://dx.doi.org/10.1016/j.abb.2021.109109.
  5. Wang Q., Wang Y., Yu Z. et al. Ammonia-induced energy disorders interfere with bilirubin metabolism in hepatocytes. Arch Biochem Biophys. 2014; 555–556: 16–22. https://dx.doi.org/10.1016/j.abb.2014.05.019.
  6. Косенко Е.А., Тихонова Л.А., Алилова Г.А. с соавт. Портокавальное шунтирование вызывает дифференциальную выработку митохондриального супероксида в областях мозга. Свободнорадикальная биология и медицина. 2017; с. 109–118. [Kosenko E.A., Tikhonova L.A., Alilova G.A. et al. Portacaval shunting causes differential mitochondrial superoxide production in brain regions. Free Radical Biology and Medicine. 2017; pp. 109–118 (In Russ.)].
  7. Felipo V., Butterworth R.F. Neurobiology of ammonia. Prog Neurobiol. 2002; 67(4): 259–79. https://dx.doi.org/10.1016/s0301-0082(02)00019-9.
  8. Adlimoghaddam A., Sabbir M.G., Albensi B.C. Ammonia as a potential neurotoxic factor in Alzheimer’s disease. Front Mol Neurosci. 2016; 9: 57. https://dx.doi.org/10.3389/fnmol.2016.00057.
  9. Cabrera-Pastor A., Arenas Y.M., Taoro-Gonzalez L. et al. Chronic hyperammonemia alters extracellular glutamate, glutamine and GABA and membrane expression of their transporters in rat cerebellum. Modulation by extracellular cGMP. Neuropharmacology. 2019; 161: 107496. https://dx.doi.org/10.1016/j.neuropharm.2019.01.011.
  10. Голованова Е.В. Аммиак – актуальная проблема врача и пациента в терапевтической практике. Терапия. 2018; 4(2): 49–55. [Golovanova E.V. Ammonia is an actual problem of a doctor and a patient in therapeutic practice. Terapiya = Therapy. 2018; 4(2): 49–55 (In Russ.)]. EDN: YUDWVO.
  11. Галеева З.М., Галиуллин О.Ф., Езюкова Е.Г., Тухбатуллина Р.Г. Гипераммониемия в клинической практике: анализ собственных клинических наблюдений. Медицинский алфавит. 2019; 4(38): 23–26. [Galeeva Z.M., Galiullin O.F., Ezyukova E.G., Tukhbatullina R.G. Hyperammonemia in clinical practice: analysis of own clinical observations. Meditsinskiy alfavit = Medical Alphabet. 2019; 4(38): 23–26 (In Russ.)]. https://dx.doi.org/10.33667/2078-5631-2019-4-38(413)-23-26. EDN: HPXAZR.
  12. Плотникова Е.Ю., Синькова М.Н., Исаков Л.К. Астения и утомление при гипераммониемии: этиопатогенез и методы коррекции. Медицинский совет. 2021; (21–1): 95–104. [Plotnikova E.Yu., Sinkova M.N., Isakov L.K. Asthenia and fatigue in hyperammonemia: etiopathogenesis and methods of correction. Meditsinskiy sovet = Medical Council. 2021; (21–1): 95–104 (In Russ.)]. https://dx.doi.org/10.21518/2079-701X-2021-21-1-95-104. EDN: XLILJK.
  13. Долгушина А.И., Кузнецова А.С., Картошкина Ю.В., Селянина А.А. Усталость и уровень аммиака капиллярной крови у студентов медицинского университета. Экспериментальная и клиническая гастроэнтерология. 2020; (4): 31–32. [Dolgushina A.I., Kuznetsova A.S., Kartoshkina Yu.V., Selyanina A.A. Fatigue and capillary blood ammonia levels in medical university students. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2020; (4): 31–32 (In Russ.)]. https://dx.doi.org/10.31146/1682-8658-ecg-176-4-31-38. EDN: APNJIQ.
  14. Granados-Fuentes D., Cho K., Patti G.J. et al. Hyperammonaemia disrupts daily rhythms reversibly by elevating glutamate in the central circadian pacemaker. Liver Int. 2023; 43(3): 673–83. https://dx.doi.org/10.1111/liv.15476.
  15. Lin F.P., Ferrando A.A., Dennis R.A. et al. Exercise induced hyperammonemia does not precipitate overt hepatic encephalopathy. Hepatology. 2020; 72(2): 778–80. https://dx.doi.org/10.1002/hep.31148.
  16. Кожевникова С.А., Трибунцева Л.В., Будневский А.В. Гипераммониемия у пациентов с хронической обструктивной болезнью легких и ожирением: механизмы ассоциации, частота выявления и возможности коррекции. Терапевтический архив. 2020; 92(2): 55–60. [Kozhevnikova S.A., Tribuntseva L.V., Budnevsky A.V. Hyperammonemia in patients with chronic obstructive pulmonary disease and obesity: Mechanisms of association, frequency of detection and possibilities for correction. Terapevticheskiy arkhiv = Therapeutic Archive. 2020; 92(2): 55–60 (In Russ.)]. https://dx.doi.org/10.26442/00403660.2020.02.000562. EDN: GXFIUM.
  17. Плотникова Е.Ю., Воросова О.А., Баранова Е.Н. с соавт. Работа в ночную смену и гипераммониемия у врачей. РМЖ. 2021; 29(4): 49–52. [Plotnikova E.Yu., Vorosova O.A., Baranova E.N. Night work and hyperammonemia in doctors. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2021; 29(4): 49–52 (In Russ.)]. EDN: MEFOYY.
  18. Nakai M., Suda G., Ogawa K. et al. Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients. PLoS One. 2022; 17(7): e0270786. https://dx.doi.org/10.1371/journal.pone.0270786.
  19. Groeneweg M., Moerland W., Quero J.C. et al. Screening of subclinical hepatic encephalopathy. J Hepatol. 2000; 32(5): 748–53. https://dx.doi.org/10.1016/s0168-8278(00)80243-3.
  20. Schomerus H., Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis. 2001; 16(1–2): 37–41. https://dx.doi.org/10.1023/a:1011610427843.
  21. Bajaj J.S., Hafeezullah M., Hoffmann R.G., Saeian K. Minimal hepatic encephalopathy: A vehicle for accidents and traffic violations. Am J Gastroenterol. 2007; 102(9): 1903–9. https://dx.doi.org/10.1111/j.1572-0241.2007.01424.x.
  22. Singh J., Sharma B.C., Puri V. et al. Sleep disturbances in patients of liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy. Metab Brain Dis. 2017; 32(2): 595–605. https://dx.doi.org/10.1007/s11011-016-9944-5.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies